Meta-analysis of 6 randomised trials (2808 patients) in HR+/HER2- advanced breast cancer after prior endocrine therapy: oral SERDs improved PFS vs standard endocrine therapy (HR 0.79), mainly in ESR1-mutated tumours (HR 0.57), with more GI adverse events.
Meta-analysisn = 2,808
Rodrigues et al. Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis